New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
17:35 EDTPAH, GGP, AGN, BEAM, AIV, PG, HMEPershing Square gives quarterly update on stakes
NEW STAKES: Platform Specialty Products (PAH), Apartment Investment and Management (AIV), Allergan (AGN), and Home Properties (HME). INCREASED STAKES: None. DECREASED STAKES: Beam (BEAM). LIQUIDATED STAKES: General Growth Properties (GGP), and Procter & Gamble (PG).
News For PAH;AIV;AGN;HME;BEAM;GGP;PG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
17:41 EDTGGPSears receives $2.7B in gross proceeds from Seritage transaction
Subscribe for More Information
09:26 EDTAGNAllergan deal wise, says BMO Capital
Subscribe for More Information
08:36 EDTAGNPiper Jaffray conference call is cancelled
Biopharmaceuticals Analyst Schimmer, along with Dr. Diana Do, a leading clinician-scientist who specializes in the treatment of retinal conditions at the University of Nebraska, discuss the current practice dynamics and treatment of wet-AMD (age-related macular degeneration), the recent AAVL Phase 2a dataset and key points of debate and emerging treatment options in wet-AMD on an Analyst/Industry conference call to be held on July 7 at 4:30 pm.
07:08 EDTAGNAllergan to acquire rights to Merck's CGRP for $250M
Subscribe for More Information
July 6, 2015
09:01 EDTPAHOM Group announces expiration of 'go shop' period
Subscribe for More Information
07:10 EDTAGNHorizon Pharma files patent infringement lawsuits against five companies
Subscribe for More Information
07:04 EDTAGNAllergan to acquire Oculeve dry eye disease development programs
Allergan and Oculeve announced that they have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction. Under the terms of the agreement, Allergan will acquire Oculeve for a $125M upfront payment and commercialization milestone payments related to Oculeve's lead development program OD-01. The agreement also includes the acquisition of an additional earlier-stage dry eye device development program. Allergan's 2015 earnings-per-share forecast provided on May 11, 2015 is unchanged as a result of the acquisition. The company remains committed to de-levering to below 3.5x debt to Adjusted EBITDA by the end of the first quarter of 2016. The acquisition of Oculeve adds novel, complementary dry eye development programs to Allergan's current eye care research and development programs, including OD-01, a non-invasive nasal neurostimulation device that increases tear production in patients with dry eye disease. Oculeve has completed four clinical studies of OD-01 to date in more than 200 patients, showing positive safety and efficacy of the device. Allergan plans to conduct two additional pivotal trials prior to FDA submission, which is expected in 2016 with potential commercial launch in 2017. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Pending approvals, Allergan anticipates closing the transaction in the third quarter of 2015.
July 1, 2015
07:25 EDTPGConsumer goods makers challenged by surging freight costs, WSJ reports
Subscribe for More Information
June 30, 2015
17:22 EDTGGPGeneral Growth files automatic mixed securities shelf
17:19 EDTPAHPershing Square lowers stake in Platform Specialty Products to 20.3% from 22.2%
15:31 EDTPGProcter & Gamble announces change to laundry pacs to improve safety
Subscribe for More Information
June 29, 2015
17:22 EDTAGNAllergan reports 6.7% stake in KYTHERA
June 25, 2015
08:13 EDTAGNAllergan CEO: Irvine campus ‘crucial’ to company, L.A. Times reports
New Allergan CEO Brent Saunders said that the company’s Irvine, California campus is “crucial” to the recently purchased organization, the L.A. Times reports, citing comments from Saunders in an interview. Allergan was purchased in March by Actavis, a move which led to the layoff of roughly 600 employees from the Irvine offices, the report says. Saunders said that the “bleeding has stopped” after a round of layoffs, the L.A. Times says. Reference Link
June 24, 2015
08:07 EDTPAHPlatform Specialty Products 15.9M share Secondary priced at $26.50
Subscribe for More Information
07:30 EDTAIVUBS to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use